Supplemental FDA funding
This article was originally published in The Tan Sheet
Executive Summary
A version of the Supplemental Appropriations Bill of 2008, H.R. 2642, passed by the Senate would provide an additional $275 million for FDA, but would likely not receive President Bush's approval, the Office of Management and Budget says May 22. The president "has made clear that he will veto a bill that ... exceeds his responsible spending levels," according to OMB Director Jim Nussle. The Senate approved the measure May 15 with $100 million in additional FDA funding to regulate drugs, devices and biologics, $50 million to modernize its science and workforce, and $125 million for food protection as well as supplement support for other domestic measures, but a same-day approval by the House did not include the additional FDA funds (1"The Tan Sheet" May 19, 2008, p. 10)...
You may also be interested in...
Additional FDA funds
FDA receives $150 million in additional funding for fiscal 2008 in the Supplemental Appropriations Bill of 2008, H.R. 2642, signed June 30 by President Bush. The appropriation includes $66.8 million for the Center for Food Safety and Applied Nutrition, $28 million for the Center for Drug Evaluation and Research and $12.7 million for the Center of Biologics Evaluation and Research. In an effort led by Pennsylvania Republican Arlen Specter, the Senate initially approved giving FDA $275 million in additional fiscal 2008 funding, including $125 million for food protection, but the administration vowed to veto those elevated spending levels (1"The Tan Sheet" May 26, 2008, In Brief). Meantime, House appropriators look for progress on fiscal 2009 appropriations despite partisan differences (see story, p. 9)...
Senate Appropriators Match Commissioner’s “Professional Judgment” Budget
A supplemental appropriations/war funding measure containing $275 million for FDA cleared the Senate Appropriations Committee May 15 but faces a tougher go in both the House and the White House
Cell/Gene Therapy Is Ripe For Real-World Data Given Length Of Follow-Up Required, Abernethy Says
The former principal deputy commissioner outlined what she sees as the future data requirements for real world evidence and why cell and gene therapy will lead the way.